ReviewBeyoglu eye journal2026
The Use of Citicoline in Ophthalmology: A systematic review.
Review in Beyoglu eye journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Citicoline is a chemical molecule, and it plays a crucial role in the biosynthesis of cell membranes and has many functions in the human body. This compound, which increases the amount of neurotransmitters, is used in the treatment of various diseases in ophthalmology, neurology, and psychiatry. Its use as a supplement to improve cognitive functions is also widespread. In this review, we aim to shed light on the neuroprotective effects of citicoline and its applications in the field of ophthalmology, based on data obtained from published studies. Methods: In the literature, the effects of citicoline in various ophthalmological diseases have been mentioned; however, there is no clear consensus regarding its dosage, duration of use, or efficacy due to the limited number of published studies and designs of these studies. Upon reviewing the current studies, we found evidence suggesting that citicoline supplementation may be effective in amblyopia, glaucoma, and non-arteritic ischemic optic neuropathy. Conclusion: This review aims to evaluate and summarize the current evidence on the neuroprotective effects of citicoline in ophthalmologic diseases. Findings from various clinical studies suggest that it may have a beneficial effect on the treatment of conditions including amblyopia, glaucoma, and non-arteritic ischemic optic neuropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.